Cerus Corporation (NASDAQ:CERS) – Investment analysts at Cantor Fitzgerald issued their FY2016 earnings estimates for Cerus Corporation in a research note issued to investors on Tuesday. Cantor Fitzgerald analyst B. Brokmeier expects that the firm will post earnings of ($0.63) per share for the year. Cantor Fitzgerald has a “Buy” rating and a $9.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Cerus Corporation’s FY2017 earnings at ($0.65) EPS.

Several other equities analysts have also weighed in on CERS. Zacks Investment Research lowered Cerus Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, January 5th. FBR & Co restated an “outperform” rating and issued a $10.00 price target on shares of Cerus Corporation in a research note on Thursday, December 22nd. Finally, BTIG Research restated a “buy” rating and issued a $10.00 price target on shares of Cerus Corporation in a research note on Thursday, October 27th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $9.75.

ILLEGAL ACTIVITY NOTICE: “Analysts Set Expectations for Cerus Corporation’s FY2016 Earnings (CERS)” was originally published by Daily Political and is the propert of of Daily Political. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be viewed at http://www.dailypolitical.com/2017/01/13/analysts-set-expectations-for-cerus-corporations-fy2016-earnings-cers.html.

Shares of Cerus Corporation (NASDAQ:CERS) traded up 2.59% during midday trading on Friday, reaching $4.36. The company’s stock had a trading volume of 314,755 shares. Cerus Corporation has a one year low of $4.17 and a one year high of $7.64. The firm’s market cap is $451.11 million. The stock’s 50 day moving average price is $4.94 and its 200 day moving average price is $5.85.

Cerus Corporation (NASDAQ:CERS) last issued its quarterly earnings data on Thursday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03. Cerus Corporation had a negative return on equity of 76.76% and a negative net margin of 174.76%. The business had revenue of $10.20 million for the quarter, compared to the consensus estimate of $10.34 million. During the same period in the prior year, the business posted ($0.17) earnings per share. The company’s quarterly revenue was up 27.5% compared to the same quarter last year. ILLEGAL ACTIVITY NOTICE: “Analysts Set Expectations for Cerus Corporation’s FY2016 Earnings (CERS)” was originally published by Daily Political and is the propert of of Daily Political. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be viewed at http://www.dailypolitical.com/2017/01/13/analysts-set-expectations-for-cerus-corporations-fy2016-earnings-cers.html.

Large investors have recently bought and sold shares of the company. US Bancorp DE boosted its stake in Cerus Corporation by 7.3% in the third quarter. US Bancorp DE now owns 16,677 shares of the company’s stock valued at $104,000 after buying an additional 1,140 shares during the last quarter. Joel Isaacson & Co. LLC boosted its stake in Cerus Corporation by 13.7% in the third quarter. Joel Isaacson & Co. LLC now owns 17,050 shares of the company’s stock valued at $106,000 after buying an additional 2,050 shares during the last quarter. Principal Financial Group Inc. purchased a new stake in Cerus Corporation during the third quarter valued at about $115,000. Nuveen Fund Advisors LLC purchased a new stake in Cerus Corporation during the second quarter valued at about $129,000. Finally, Meristem LLP purchased a new stake in Cerus Corporation during the third quarter valued at about $155,000. Institutional investors own 68.36% of the company’s stock.

Cerus Corporation Company Profile

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

5 Day Chart for NASDAQ:CERS

Receive News & Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related companies with MarketBeat.com's FREE daily email newsletter.